T. Rowe Price Associates’s Arcutis Biotherapeutics ARQT Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Shares Change % | Capital Flow | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2025
Q2 | $1.18M | Buy |
84,047
+6,107
| +8% | +$85.7K | ﹤0.01% | 1907 |
|
|
2025
Q1 | $1.22M | Buy |
77,940
+35,591
| +84% | +$557K | ﹤0.01% | 1852 |
|
|
2024
Q4 | $590K | Sell |
42,349
-17,799
| -30% | -$248K | ﹤0.01% | 2209 |
|
|
2024
Q3 | $560K | Buy |
60,148
+1,246
| +2% | +$11.6K | ﹤0.01% | 2202 |
|
|
2024
Q2 | $548K | Buy |
58,902
+11,149
| +23% | +$104K | ﹤0.01% | 2156 |
|
|
2024
Q1 | $474K | Buy |
47,753
+1,681
| +4% | +$16.7K | ﹤0.01% | 2231 |
|
|
2023
Q4 | $149K | Buy |
46,072
+23,125
| +101% | +$74.8K | ﹤0.01% | 2628 |
|
|
2023
Q3 | $122K | Buy |
22,947
+622
| +3% | +$3.31K | ﹤0.01% | 2620 |
|
|
2023
Q2 | $213K | Buy |
22,325
+2,560
| +13% | +$24.4K | ﹤0.01% | 2501 |
|
|
2023
Q1 | $218K | Buy |
19,765
+519
| +3% | +$5.72K | ﹤0.01% | 2484 |
|
|
2022
Q4 | $285K | Sell |
19,246
-160,048
| -89% | -$2.37M | ﹤0.01% | 2388 |
|
|
2022
Q3 | $3.43M | Sell |
179,294
-273,763
| -60% | -$5.23M | ﹤0.01% | 1275 |
|
|
2022
Q2 | $9.66M | Buy |
453,057
+4,355
| +1% | +$92.8K | ﹤0.01% | 1320 |
|
|
2022
Q1 | $8.64M | Sell |
448,702
-374,466
| -45% | -$7.21M | ﹤0.01% | 1384 |
|
|
2021
Q4 | $17.1M | Buy |
823,168
+9,474
| +1% | +$196K | ﹤0.01% | 1320 |
|
|
2021
Q3 | $19.4M | Sell |
813,694
-111,264
| -12% | -$2.66M | ﹤0.01% | 1304 |
|
|
2021
Q2 | $25.2M | Buy |
924,958
+268,537
| +41% | +$7.33M | ﹤0.01% | 1241 |
|
|
2021
Q1 | $19M | Buy |
656,421
+393,640
| +150% | +$11.4M | ﹤0.01% | 1284 |
|
|
2020
Q4 | $7.39M | Sell |
262,781
-728,240
| -73% | -$20.5M | ﹤0.01% | 1388 |
|
|
2020
Q3 | $29M | Sell |
991,021
-75,519
| -7% | -$2.21M | ﹤0.01% | 1044 |
|
|
2020
Q2 | $32.3M | Buy |
1,066,540
+85,926
| +9% | +$2.6M | ﹤0.01% | 991 |
|
|
2020
Q1 | $29.2M | Buy |
+980,614
| New | +$29.2M | ﹤0.01% | 950 |
|